pyrroles has been researched along with Local Neoplasm Recurrence in 127 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.79) | 18.2507 |
| 2000's | 25 (19.69) | 29.6817 |
| 2010's | 86 (67.72) | 24.3611 |
| 2020's | 15 (11.81) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MP; Ferraldeschi, R; Ferrari, N; Gewinner, C; Jueliger, S; Keer, H; Lyons, J; Munck, J; Saini, H; Sims, MJ; Smyth, T; Ward, G | 1 |
| Das, M; Owonikoko, TK; Padda, SK; Weiss, J | 1 |
| Féliz, L; Gutierrez, M; Iannotti, NO; Ji, T; Lihou, CF; Saleh, M; Silverman, IM; Smith, DC; Subbiah, V; Tian, C | 1 |
| Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S | 1 |
| Doki, Y; Eguchi, H; Hirota, S; Kurokawa, Y; Makino, T; Motoori, M; Nakajima, K; Nishida, T; Omori, T; Saito, T; Takahashi, T; Tanaka, K; Teranishi, R; Yamamoto, K; Yamashita, K | 1 |
| Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; de Bruin, EC; Foxley, A; Howell, SJ; Ingarfield, K; Jones, RH; Meissner, M; Moon, S; Morgan, S; Schiavon, G; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Liu, X; Tang, J; Wang, S; Wu, H; Zhang, Y; Zhao, J; Zhou, J | 1 |
| Ardeshna, KM; Boni, J; Caimi, P; Carlo-Stella, C; Feingold, JM; Hamadani, M; Havenith, K; He, S; Heffner, LT; Kahl, BS; O'Connor, OA; Radford, J; Reid, E; Solh, M; Ungar, D | 1 |
| Alchami, F; Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; Cox, C; Foxley, A; Howell, SJ; Joffe, J; Jones, RH; Madden, TA; Moon, S; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Abou-Alfa, GK; Al-Rajabi, R; Borad, MJ; Catenacci, DV; Dotan, E; Féliz, L; Gallinson, D; Hollebecque, A; Ji, T; Lihou, CF; Melisi, D; Murphy, AG; Oh, DY; Paulson, AS; Sahai, V; Vaccaro, G; Van Cutsem, E; Vogel, A; Zhen, H | 1 |
| Akiyoshi, H; Mie, K; Miura, N; Nishida, H; Tanaka, T; Yamazaki, H | 1 |
| Donati, DM; Longhi, A; Palmerini, E; Staals, EL | 1 |
| Baldi, GG; Gronchi, A; Stacchiotti, S | 1 |
| Adderley, T; Christopher, G; Irwin, MS; Kano, Y; Kee, L; Ladumor, Y; Ohh, M; Robinson, CM; Valencia-Sama, I | 1 |
| Chen, CT; Deshpande, V; Goyal, L; Pierce, TT | 1 |
| Aiba, M; Ito, S; Nagai, J; Tateno, T; Tsutsumi, Y | 1 |
| Dong, Z; Gao, J; Gong, J; Li, J; Li, Y; Shen, L | 1 |
| Argyle, DJ; Bavcar, S; Buracco, P; de Fornel, P; de Vos, J; Hirschberger, J; Kessler, M; Murphy, S | 1 |
| Ma, H; Su, Z; Sun, F; Zhao, N | 1 |
| Ishikawa, S; Katagiri, A; Kazama, A; Mizusawa, T | 1 |
| Bersanelli, M; Buti, S; DiPaola, RS; Haas, NB; Manola, J; Puligandla, M; Taguchi, S | 1 |
| Grammatico, S; Petrucci, MT; Scalzulli, E; Vozella, F | 1 |
| Agati, R; Bartolini, S; Brandes, AA; Di Battista, M; Franceschi, E; Genestreti, G; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A | 1 |
| Brady, W; Brown, J; Chan, JK; Gershenson, DM; Kim, JH; Monk, BJ; Rose, PG; Secord, AA; Shahin, MS; Walker, JL | 1 |
| Aschelter, AM; Capriotti, G; Cerquetti, L; Lardo, P; Marchetti, P; Matarazzo, I; Nardone, MR; Petrangeli, E; Schiavi, F; Stigliano, A; Toscano, V | 1 |
| Barr, PM; Boyd, T; Caimi, PF; Carret, AS; Chen, R; Chhabra, S; Gartner, EM; Kingsley, EC; Kolibaba, K; Li, H; Park, SI; Phillips, T; Smith, DC; Yu, C | 1 |
| Barata, PC; Cooney, M; Dreicer, R; Garcia, JA; Gupta, R; Mendiratta, P | 1 |
| Hama, Y; Hayata, N; Masuda, N; Satogami, N; Segawa, T; Sunada, T; Yoshida, T; Yoshikawa, T | 1 |
| Alarcón, E; Armstrong, AC; Cheung, SYA; Corcoran, C; Cullberg, M; Davies, BR; de Bruin, EC; Foxley, A; Gómez Villanueva, A; Lindemann, JPO; López Chuken, YA; Maudsley, R; Moschetta, M; Oliveira, M; Outhwaite, E; Pass, M; Pérez-Fidalgo, JA; Philco, M; Rugman, P; Sablin, MP; Schiavon, G; Tamura, K; Turner, NC | 1 |
| Du, Y; Fang, J; Guo, X; Jin, Y; Liang, X; Lu, W; Sun, W; Tian, J; Yu, C; Zheng, J | 1 |
| Ba-Ssalamah, A; Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Högenauer, C; Kastner, U; Kühr, T; Längle, F; Liegl-Atzwanger, B; Ploner, F; Schoppmann, SF; Widmann, G; Wrba, F; Zacherl, J | 1 |
| Ji, T; Ong, HS; Wang, LZ; Yu, ZW; Zhang, CP | 1 |
| Brearley, M; Dobson, J; Marcinowska, A; Warland, J | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Li, J; Shi, Y; Xing, P | 1 |
| Buchroithner, J; Capper, D; Embacher, S; Gotwald, T; Haybaeck, J; Herrlinger, U; Holzner, B; Hutterer, M; Marosi, C; Moik, M; Nowosielski, M; Oberndorfer, S; Preusser, M; Seiz, M; Stockhammer, F; Stockhammer, G; Tuettenberg, J; Vajkoczy, P; Wick, A | 1 |
| Adams, JW; Berger, MS; Chiappori, A; Edelman, MJ; Haura, EB; Malik, S; Northfelt, DW; Rosen, P; Van Echo, DA; Williams, C | 1 |
| Berger, M; Ford, P; Goy, A; Hernandez-Ilzaliturri, FJ; Kahl, B; Protomastro, E | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Blattler, C; Castonguay, V; Fleming, G; Hirte, H; Ivy, PS; Lheureux, S; Mackay, HJ; Morgan, R; Oza, AM; Wang, L; Welch, S | 1 |
| Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E | 1 |
| Andrews, DW; Axelrod, R; Camphausen, K; Curran, WJ; Dicker, AP; Evans, J; Glass, J; Haacke, EM; Hillman, GG; Lin, A; Shi, W; Werner-Wasik, M; Wuthrick, EJ | 1 |
| Hongo, F; Kamoi, K; Miki, T; Naitoh, Y; Nakamura, T; Naya, Y; Oishi, M; Okihara, K; Ueda, T | 1 |
| Anjum, R; Bauer, S; Clackson, T; Eilers, G; Fletcher, JA; Garner, AP; Gozgit, JM; Heinrich, MC; Ketzer, J; Kohlmann, A; Ning, Y; Rivera, VM; Schrock, A; Serrano, C; Song, Y; Vodala, S; Wang, F; Wardwell, S; Zhou, T; Zhu, M | 1 |
| Achen, MG; Chander, S; Choong, PF; Desai, J; Ferris, N; Fox, S; Herschtal, A; Hicks, RJ; Khamly, KK; Lewin, J; Mitchell, C; Ngan, SY; Powell, GJ; Slavin, J; Stacker, SA; Te Marvelde, L; Thomas, DM; Toner, GC; Young, RJ | 1 |
| Rahman, A | 1 |
| Berman, A; Brzezniak, C; Carter, CA; Giaccone, G; Guha, U; Lee, MJ; Lee, S; Ling, A; Loehrer, PJ; Meltzer, P; Rajan, A; Spittler, AJ; Steinberg, SM; Szabo, E; Thomas, A; Tomita, Y; Trepel, JB; Wang, Y | 1 |
| Marx, A; Weis, CA | 1 |
| Hohenberger, P; Jakob, J; Kasper, B; Ronellenfitsch, U; Simeonova, A; Wenz, F | 1 |
| Ahluwalia, MS; Angelov, L; Barnett, GH; Brewer, CJ; Chao, ST; Elson, P; Mikkelsen, T; Parsons, MW; Peereboom, DM; Rump, M; Schilero, C; Smolenski, KN; Suh, JH; Vogelbaum, MA; Wang, D; Weil, RJ | 1 |
| Auberger, P; Belaid, A; Benhida, R; Colosetti, P; Cormerais, Y; Dufies, M; Giuliano, S; Grépin, R; Lacas-Gervais, S; Martin, A; Mazure, NM; Mograbi, B; Pagès, G; Parola, J | 1 |
| Berk, V; Bozkurt, O; Duran, AO; Duzkopru, Y; Hacıbekiroglu, I; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M; Ucar, M; Uysal, M | 1 |
| Rexer, H | 1 |
| Du Four, S; Duerinck, J; Everaert, H; Hau, P; Michotte, A; Neyns, B; Sander, W; Van Binst, AM | 1 |
| Billingham, LJ; Buller, R; Carr, TH; Crack, LR; Hollingsworth, SJ; Middleton, G; Popat, S; Swanton, C; Walker, I; Wherton, D | 1 |
| Butowski, N; Cloughesy, TF; Colman, H; De Groot, JF; Haidar, S; Hsu, HH; Huse, J; Ligon, KL; Marimuthu, A; Molinaro, AM; Nayak, L; Nolop, KB; Omuro, AM; Perry, A; Phillips, J; Prados, M; Wen, PY; West, BL | 1 |
| Abdelraouf, F; Baas, P; Hasan, B; Menis, J; O'Brien, M; Popat, S; Smit, E; Surmont, VF; van Meerbeeck, JP | 1 |
| Anand, M; Armstrong, AJ; Bratt, L; Carducci, MA; Creel, P; Davis, K; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kim, S; Koontz, BF; Lee, WR; Moul, JW; Mundy, K; Nguyen, M; Reimer, B; Stein, M; Tran, PT; Wood, S | 1 |
| Billups, CA; Blaney, SM; Boyett, JM; Daryani, VM; Gajjar, A; Goldsmith, KC; Leary, S; Stewart, CF; Tanos, R; Wetmore, C | 1 |
| Barkhodari, A; Harshman, L; Minamimoto, R; Quon, A; Srinivas, S | 1 |
| Ding, Y; Gu, X; Wang, L; Wang, R; Wang, Z; Wei, L; Zhang, Y; Zhao, D | 1 |
| Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Quivy, A; Ravaud, A | 1 |
| Bi, L; Gomez, M; Haug, J; Kimlinger, T; Kumar, S; Mukhopadhyay, B; Painuly, U; Prasad, V; Rajkumar, SV; Ramakrishnan, V | 1 |
| Ding, L; Meng, X; Song, S; Sun, B; Wu, S; Zhao, X | 1 |
| Bocchia, M; Brambilla, CZ; Candi, V; Gozzetti, A; Papini, G; Sirianni, S | 1 |
| Chen, T; Chen, Z; Feng, X; Li, G; Li, Y; Qiu, H; Sun, X; Tao, K; Yu, J; Zhang, P; Zhou, Z | 1 |
| Baines, L; Elliott, JW; Parry, A; Swinbourne, F | 1 |
| Falkowski, S; Jagodzińska-Mucha, P; Klimczak, A; Koseła-Paterczyk, H; Kozak, K; Rogala, P; Rutkowski, P; Świtaj, T; Wągrodzki, M; Ługowska, I | 1 |
| Bierer, S; Bolenz, C; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
| Hur, H; Jee, SB; Jeon, HM; Jung, SE; Kim, W; Park, AR | 1 |
| Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J | 1 |
| Kim, EA; Kwon, Y; Lee, KS; Park, IH; Ro, J | 1 |
| Hartmann, JT; Kanz, L | 1 |
| Kamposioras, K; Mauri, D; Panou, C; Tsali, L; Valachis, A | 1 |
| Clohisy, DR; Frolich, JW; Manivel, JC; Skubitz, KM | 1 |
| Gordon, I; Khanna, C | 1 |
| Bergman, PJ; Boucher, JF; Couto, GC; Henry, CJ; Hintermeister, JG; Klein, MK; London, CA; Malpas, PB; Mauldin, GN; Michels, GM; Mitchener, KL; Rosenberg, MP; Rusk, AW; Wood-Follis, SL | 1 |
| Andreiuolo, F; Bobos, M; Calderaro, J; Fountzilas, G; Fragkoulidi, A; Kalogera-Fountzila, A; Marselos, M; Nikolaidou, M | 1 |
| Eisenhauer, EA; Ivy, P; Mackay, HJ; Oza, A; Sederias, J; Swenerton, K; Thomas, G; Tinker, A; Winquist, E | 1 |
| Bosscher, JR; Brown, J; Debernardo, RL; Gehrig, PA; Hartenbach, EM; Hensley, ML; McCourt, CK; Scribner, DR; Sill, MW | 1 |
| Dieckmann, K; Elandt, K; Hutterer, M; Koperek, O; Marosi, C; Prayer, D; Preusser, M; Sohm, M | 1 |
| Bompas, E; Dillies, AF; Duprez, T; Faivre, S; Guigay, J; Henry, S; Kaminsky, MC; Machiels, JP; Michoux, N; Moxhon, A; Rommel, D; Schmitz, S; Zanetta, S | 1 |
| Patel, SR; Pisters, PW | 1 |
| Bao-Hui, H; Hui-Min, W; Ping, G; Wei-Min, W | 1 |
| Hansen, T; Jäger, E; Koch, FP; Wagner, W; Walter, C | 1 |
| Gnant, M | 1 |
| Aubin, F; Blanke, CD | 1 |
| Ganjoo, KN; Patel, S | 1 |
| Raut, CP; Winer, JH | 1 |
| Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T; Yamamoto, M | 1 |
| Carrato, A; Ferreiro, R; Grande, E; Pachón, V; Vaz, MA | 1 |
| Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Jung, SM; Lee, CC; Tsai, CS; Wang, CC; Wen, CJ | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ | 1 |
| Chau, NG; Chen, EX; Chin, SF; Hotte, SJ; Siu, LL; Turner, S; Wang, L | 1 |
| Awada, A; Bergh, J; Cardoso, F; Gianni, L; Giorgetti, C; Huang, X; Kern, KA; Liljegren, A; Mariani, G; Verkh, L; Viganò, L | 1 |
| Bauerschlag, D; Baumann, KH; Canzler, U; Dewitz, T; du Bois, A; Hanker, LC; Hasenburg, A; Hillemanns, P; Hilpert, F; Kurzeder, C; Meier, W; Rau, J; Richter, B; Sehouli, J; Wagner, U; Wimberger, P; Wollschlaeger, K | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Heidenreich, A; van Essen, J | 1 |
| He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y | 1 |
| Bonenkamp, JJ; de Wilt, JH; Gelderblom, H; Hartgrink, HH; Sleijfer, S; Tielen, R; van Coevorden, F; van der Graaf, WT; Verhoef, C | 1 |
| Casali, PG; De Troia, B; Dei Tos, AP; Gronchi, A; Libertini, M; Marrari, A; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S | 1 |
| Athanasou, NA; Bradley, KM; Dijkstra, PD; Gelderblom, H; Gibbons, CL; Hassan, AB; Hogendoorn, PC; Kroep, JR; Nout, RA; van de Sande, MA; van der Heijden, L; van Rijswijk, CS | 1 |
| Chamberlain, M; Chowdhary, S; Pan, E; Potthast, L; Smith, P; Yu, D; Yue, B | 1 |
| Berlin, S; Campos, SM; Horowitz, NS; Matulonis, U; Penson, RT; Pereira, L; Roche, M; Szymonifka, J; Tyburski, K; Whalen, C | 1 |
| Gallowitsch, HJ; Malle, P; Sorschag, M | 1 |
| Bagot, M; Basset-Seguin, N; Battistella, M; Bouaziz, JD; Comte, C; Farges, C; Kerob, D; le Maignan, C; Lebbé, C; Madjessli, N; Pagès, C; Penot, P; Vilmer, C | 1 |
| Anderson, J; Bier, N; Cherian, A; Chowdhury, T; O'Meara, A; Prichard-Jones, K; Sebire, NJ; Sullivan, MO | 1 |
| Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L | 1 |
| Fine, HA; Iwamoto, FM; Kreisl, TN; Salgado, C; Shih, JH; Smith, P; Sul, J | 1 |
| Han, JH; Han, JY; Kim, HJ; Kim, HT; Kim, HY; Kwak, MH; Lee, JS; Lee, YJ; Lim, KY; Yun, T | 1 |
| Donnelly, E; Geng, L; Hallahan, DE; Himmelfarb, E; McMahon, G; Mendel, D; Schueneman, AJ; Tan, J | 1 |
| Cooney, MM; Dowlati, A; Hoppel, CL; Ingalls, ST; Ivy, P; Ksenich, P; Lavertu, P; Makar, V; McCrae, K; McPeak, RJ; Overmoyer, B; Remick, S; Tserng, KY | 1 |
| de Wit, M; Fiedler, W; Höltje, J; Hossfeld, DK; Jacobs, MS; Laack, E; Schilling, G; Schuch, G; Scigalla, P | 1 |
| Berghaus, A; Dellian, M; Eichhorn, ME; Jonczyk, A; Strieth, S; Sutter, A | 1 |
| Aliff, T; Fleisher, M; Fury, MG; Gerald, W; Hann, L; Lis, E; Pfister, DG; Venkatraman, E; Wong, R; Zahalsky, A | 1 |
| Blanke, CD; Schnadig, ID | 1 |
| Joensuu, H | 1 |
| Belcaceres, JL; Cojocarasu, O; Halimi, P; Medioni, J; Oudard, S | 1 |
| Astorino, M; Biasco, G; Brandi, G; Castellucci, P; Catena, F; Di Battista, M; Di Scioscio, V; Pantaleo, MA; Piazzi, G; Santini, D; Saponara, M | 1 |
| Atkins, JN; Belani, CP; Brahmer, JR; Chao, RC; Gillenwater, HH; Govindan, R; Novello, S; Pallares, C; Rosell, R; Sanchez, JM; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L | 1 |
| Dudek, AZ; Mulamalla, K; Truskinovsky, AM | 1 |
| Brown, JE; Hall, PS; Kancherla, K; Sastry, PS | 1 |
| Avakian, R; Belldegrun, AS; Kabbinavar, FF; LaRochelle, JC; Pantuck, AJ; Patard, JJ; Riggs, SB; Shuch, B | 1 |
| Jonasch, E; Margulis, V; Matin, SF; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG | 1 |
| Angelov, L; Guha, A; McMahon, G; Roncari, L; Salhia, B | 1 |
18 review(s) available for pyrroles and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma | 2021 |
Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Topics: Adult; Aminopyridines; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Giant Cell Tumor of Tendon Sheath; Humans; Macrophage Colony-Stimulating Factor; Neoplasm Recurrence, Local; Pyrroles; Quality of Life | 2020 |
Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Topics: Adult; Aminopyridines; Antineoplastic Agents; Giant Cell Tumor of Tendon Sheath; Humans; Macrophage Colony-Stimulating Factor; Neoplasm Recurrence, Local; Pyrroles; Quality of Life; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2020 |
Proteasome inhibitors for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Hematologic Diseases; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles | 2018 |
Dermatofibrosarcoma protuberans on the right neck with superior vena cava syndrome: case report and literature review.
Topics: Adult; Antineoplastic Agents; Dermatofibrosarcoma; Head and Neck Neoplasms; Humans; Indoles; Male; Neck; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Superior Vena Cava Syndrome; Thorax; Vena Cava, Superior | 2013 |
Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2016 |
Second Generation Proteasome Inhibitors in Multiple Myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Drug Discovery; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles; Threonine | 2017 |
Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Female; Fibromatosis, Aggressive; Follow-Up Studies; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2009 |
Gastrointestinal stromal tumors: current management.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Neoadjuvant treatment and breast conserving surgery - a success of clinical research in breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Indoles; Mastectomy, Segmental; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Protein-Tyrosine Kinases; Pyrroles; Radiotherapy; Randomized Controlled Trials as Topic; Sunitinib | 2010 |
Metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Indoles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-kit; Pyrroles; Salvage Therapy; Sunitinib | 2011 |
Current and emerging pharmacological treatments for gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Drugs, Investigational; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Management of recurrent gastrointestinal stromal tumors.
Topics: Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal.
Topics: Adult; Antineoplastic Agents; Arthroplasty; Arthroscopy; Benzamides; Chemotherapy, Adjuvant; Female; Giant Cell Tumors; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Radioisotopes; Radiotherapy, Adjuvant; Sunitinib; Synovectomy; Synovial Membrane; Tendons; Tenosynovitis | 2013 |
FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Multimodal Imaging; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Gastrointestinal stromal tumors: imatinib and beyond.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2006 |
Second line therapies for the treatment of gastrointestinal stromal tumor.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2007 |
48 trial(s) available for pyrroles and Local Neoplasm Recurrence
| Article | Year |
|---|---|
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Female; Fibroblast Growth Factors; Humans; Lung Neoplasms; Male; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2022 |
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Neoplasm Recurrence, Local; Pyrroles; Sulfonamides | 2022 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomar
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Agents; Benzodiazepines; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoconjugates; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Salvage Therapy; Survival Rate; Young Adult | 2019 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2020 |
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Topics: Adult; Aged; Cholangiocarcinoma; Drug-Related Side Effects and Adverse Reactions; Female; Fibroblast Growth Factors; Humans; Male; Middle Aged; Morpholines; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Fibroblast Growth Factor | 2020 |
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Health Status Indicators; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrroles; Sunitinib; Young Adult | 2018 |
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Benzodiazepines; Biomarkers, Tumor; CD27 Ligand; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Salvage Therapy; Tissue Distribution | 2019 |
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Bevacizumab; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Salvage Therapy; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2019 |
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Estrogen; Survival Rate | 2019 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrroles; Sunitinib; Survival Rate | 2014 |
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Indoles; Lung Neoplasms; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Pyrroles; Taxoids | 2014 |
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; California; Carcinosarcoma; Chicago; Endometrial Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ontario; Pyrroles; Sunitinib | 2014 |
A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prospective Studies; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Sunitinib | 2014 |
Sunitinib for atypical and anaplastic meningioma.
Topics: Angiogenesis Inhibitors; Confidence Intervals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Pyrroles; Single-Blind Method; Sunitinib; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Prognosis; Pyrroles; Sunitinib; Survival Rate; Thymoma; Thymus Neoplasms | 2015 |
Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemoradiotherapy; Extremities; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Prospective Studies; Pyrroles; Radiotherapy, Adjuvant; Retroperitoneal Neoplasms; Sarcoma; Sunitinib | 2015 |
Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cognition Disorders; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neuropsychological Tests; Pyrroles; Radiosurgery; Salvage Therapy; Sunitinib; Treatment Outcome | 2015 |
[Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal c
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Indoles; Lomustine; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Temozolomide | 2015 |
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Translational Research, Biomedical; United Kingdom | 2015 |
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Topics: Administration, Oral; Aminopyridines; Biomarkers, Tumor; Blood-Brain Barrier; Brain Neoplasms; Cohort Studies; Female; Follow-Up Studies; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tissue Distribution; Tumor Burden | 2016 |
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Patient Selection; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Sample Size; Small Cell Lung Carcinoma; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Topics: Adult; Aged; Disease-Free Survival; Docetaxel; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrroles; Quality of Life; Salvage Therapy; Sunitinib; Taxoids | 2016 |
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Drug Monitoring; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Indoles; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Pyrroles; Retreatment; Sunitinib; Treatment Outcome; Young Adult | 2016 |
A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
Topics: Aged; Angiogenesis Inhibitors; Anorexia; Area Under Curve; Carcinoma, Squamous Cell; Drug Administration Schedule; Fatigue; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Uterine Cervical Neoplasms | 2010 |
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Indoles; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Uterine Neoplasms | 2009 |
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Indoles; Magnetic Resonance Angiography; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2010 |
Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2011 |
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Young Adult | 2011 |
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids | 2012 |
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Adenoid Cystic; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Proto-Oncogene Mas; Pyrroles; Salivary Gland Neoplasms; Sunitinib; Treatment Outcome | 2012 |
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Treatment Outcome | 2012 |
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monother
Topics: Angiogenesis Inhibitors; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Platinum Compounds; Proportional Hazards Models; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2012 |
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Female; Glioma; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2012 |
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2013 |
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Continuous daily sunitinib for recurrent glioblastoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Quality of Life; Sunitinib; Survival Rate | 2013 |
A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asthenia; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Head and Neck Neoplasms; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles | 2005 |
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Pressure; Female; Head and Neck Neoplasms; Heart Rate; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Pyrroles; Regional Blood Flow; Ultrasonography; Vascular Endothelial Growth Factor A | 2007 |
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pain; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Stomatitis; Sunitinib; Treatment Outcome | 2008 |
61 other study(ies) available for pyrroles and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma.
Topics: Apoptosis; Humans; Immunity; Lymphoma, T-Cell; Morpholines; Neoplasm Recurrence, Local; Piperazines; Pyrroles; Skin Neoplasms | 2021 |
Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors.
Topics: Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Indoles; Japan; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies | 2022 |
A conductive gelatin methacrylamide hydrogel for synergistic therapy of osteosarcoma and potential bone regeneration.
Topics: Bentonite; Bone Neoplasms; Bone Regeneration; Cell Line, Tumor; Doxorubicin; Gelatin; Humans; Hydrogels; Hyperthermia, Induced; Neoplasm Recurrence, Local; Osteosarcoma; Phototherapy; Polymers; Pyrroles | 2023 |
Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
Topics: Adenocarcinoma; Animals; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dog Diseases; Dogs; Female; Indoles; Male; Neoplasm Recurrence, Local; Neoplasms; Pyrroles; Retrospective Studies; Treatment Outcome; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, ras; Heterografts; Humans; Indoles; Male; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Recurrence, Local; Neuroblastoma; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Triazoles; Vemurafenib | 2020 |
Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma.
Topics: Adenocarcinoma; Adult; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Fatal Outcome; Female; Hepatectomy; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pyrazoles; Pyrimidines; Pyrroles; Tomography, X-Ray Computed | 2021 |
Convulsive Seizure Due to Hypomagnesemia Caused by Short-term Vonoprazan Intake.
Topics: Aged; Double-Blind Method; Female; Humans; Magnesium; Neoplasm Recurrence, Local; Proton Pump Inhibitors; Pyrroles; Seizures; Sulfonamides | 2022 |
Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Drug Substitution; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Sunitinib; Treatment Failure; Treatment Outcome | 2017 |
Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Europe; Indoles; Lomustine; Mast Cells; Neoplasm Recurrence, Local; Prednisolone; Prospective Studies; Pyrroles; Receptor Protein-Tyrosine Kinases; Skin Neoplasms | 2017 |
The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles; Retrospective Studies | 2018 |
Continuous remission of renal cell carcinoma with tumour thrombus after severe adverse events following short-term treatment with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pyrroles; Remission Induction; Sunitinib; Thrombosis; Vena Cava, Inferior | 2017 |
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
Topics: Acetanilides; Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Quinolines; Retreatment; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2018 |
Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Paraganglioma; Pyrroles; Succinate Dehydrogenase; Sunitinib; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2018 |
[A Case of Metastatic Clear Cell Renal Cell Carcinoma Showing Long-Term Complete Response after the Discontinuation of Tyrosine Kinase Inhibitor].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Pyrroles | 2018 |
Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Female; Fluorescence; Hyaluronic Acid; Hyperthermia, Induced; Immunity; Immunotherapy; Mammary Neoplasms, Animal; Mice; Nanoparticles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Optical Imaging; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles; Tissue Distribution | 2019 |
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.
Topics: Adult; Aftercare; Austria; Benzamides; Biopsy; Child; Combined Modality Therapy; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Mitotic Index; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Nomograms; Palliative Care; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2013 |
A novel approach to treatment of lymphangiosarcoma in a boxer dog.
Topics: Animals; Antibiotics, Antineoplastic; Dog Diseases; Dogs; Doxorubicin; Female; Indoles; Lymphangiosarcoma; Mammary Glands, Animal; Mammary Neoplasms, Animal; Neoplasm Recurrence, Local; Pyrroles; Survival Rate; Treatment Outcome | 2013 |
[Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2013 |
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2015 |
A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioma; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Pyrroles; Radiosurgery; Remission Induction; Retreatment; Sunitinib | 2014 |
Complete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case report.
Topics: Adult; Carcinoma, Renal Cell; Humans; Indoles; Kidney; Kidney Neoplasms; Kidney Transplantation; Male; Neoplasm Recurrence, Local; Postoperative Care; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Sunitinib in thymic carcinoma: enigmas still unresolved.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pyrroles; Sunitinib; Thymoma; Thymus Neoplasms | 2015 |
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
Topics: Angiogenesis Inhibitors; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; Lysosomes; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; Turkey | 2015 |
Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Glycolysis; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.
Topics: Adult; Antineoplastic Agents; Cetuximab; ErbB Receptors; Esthesioneuroblastoma, Olfactory; Genotyping Techniques; Humans; Indoles; Magnetic Resonance Imaging; Male; Mutation; Nasal Cavity; Neoplasm Recurrence, Local; Nose Neoplasms; Precision Medicine; Proto-Oncogene Proteins c-ret; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Multiple Myeloma; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Thiazoles; Unfolded Protein Response; Up-Regulation; X-Box Binding Protein 1 | 2016 |
Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Salvage Therapy; Sunitinib; Treatment Outcome; Ulcer | 2016 |
[Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Combined Modality Therapy; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2016 |
Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia).
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Female; Gastrointestinal Stromal Tumors; Indoles; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Pyrroles | 2017 |
Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma.
Topics: Adult; Aged; Bone Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sarcoma, Alveolar Soft Part; Sunitinib | 2017 |
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Surveys; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Quality of Life; Salvage Therapy; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Perforation; Male; Neoplasm Recurrence, Local; Peritonitis; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2009 |
Major response to sunitinib (Sutene) in metastatic malignant phyllodes tumor of breast.
Topics: Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phyllodes Tumor; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.
Topics: Chemotherapy, Adjuvant; Follow-Up Studies; Hair Color; Humans; Hypopigmentation; Ileum; Indoles; Intestinal Neoplasms; Leiomyoma; Male; Middle Aged; Neoplasm Recurrence, Local; Periodicity; Proto-Oncogene Proteins c-kit; Pyrroles; Risk Assessment; Sunitinib; Twins, Monozygotic | 2008 |
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Histiocytoma, Malignant Fibrous; Humans; Indoles; Kidney Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Catching cancer by the tail: new perspectives on the use of kinase inhibitors.
Topics: Animals; Dog Diseases; Dogs; Indoles; Mast-Cell Sarcoma; Neoplasm Recurrence, Local; Pyrroles; Random Allocation; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2009 |
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
Topics: Animals; Anorexia; Diarrhea; Disease Progression; Dog Diseases; Dogs; Female; Indoles; Male; Mast-Cell Sarcoma; Neoplasm Recurrence, Local; Pyrroles; Random Allocation; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Vomiting | 2009 |
Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.
Topics: Aged; Antineoplastic Agents; Esthesioneuroblastoma, Olfactory; Humans; Immunohistochemistry; Indoles; Male; Nasal Cavity; Neoplasm Recurrence, Local; Nose Neoplasms; Pyrroles; Salvage Therapy; Sunitinib | 2010 |
Osteonecrosis of the jaw related to sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Mandibular Diseases; Middle Aged; Molar; Neoplasm Recurrence, Local; Nephrectomy; Osteonecrosis; Postoperative Complications; Pyrroles; Sunitinib; Tooth Extraction | 2011 |
Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiography; Sunitinib | 2011 |
Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Remission Induction; Sunitinib; Treatment Outcome | 2011 |
Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Transplantation; Cell Aggregation; Cell Hypoxia; Cell Line, Tumor; Coloring Agents; Drug Resistance, Neoplasm; Endothelial Cells; Green Fluorescent Proteins; Indoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neovascularization, Pathologic; Nitroimidazoles; Prostatic Neoplasms; Pyrroles; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Salvage Therapy; Sunitinib; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
[Metastatic apocrine adenocarcinoma of the penis: cytostatic therapy].
Topics: Adult; Antineoplastic Agents; Apocrine Glands; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Humans; Indoles; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Penile Neoplasms; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Sweat Gland Neoplasms; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2012 |
Sunitinib malate in solitary fibrous tumor (SFT).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, CD34; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies; Solitary Fibrous Tumors; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate.
Topics: Adult; Amputation Stumps; Amputation, Surgical; Antineoplastic Agents; Axilla; Drug Administration Schedule; Forearm; Hand; Humans; Indoles; Male; Muscle Neoplasms; Neoplasm Recurrence, Local; Pyrroles; Sarcoma; Skin Neoplasms; Sunitinib; Treatment Outcome; Umbilicus | 2013 |
Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Child; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Remission Induction; Sunitinib; Tomography, X-Ray Computed; Translocation, Genetic | 2013 |
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Lewis Lung; Combined Modality Therapy; Endothelium, Vascular; Glioblastoma; Humans; Indoles; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2003 |
Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416.
Topics: Angiogenesis Inhibitors; Biopsy, Needle; Cerebellar Neoplasms; Diagnosis, Differential; Follow-Up Studies; Hemangioblastoma; Humans; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Risk Assessment; Treatment Outcome; von Hippel-Lindau Disease | 2005 |
Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cricetinae; Disease Progression; Indoles; Integrin alphaV; Male; Mesocricetus; Microcirculation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrroles; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2007 |
Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2008 |
Rare case of hemangiopericytoma responds to sunitinib.
Topics: Angiogenesis Inhibitors; Bone Neoplasms; Hemangiopericytoma; Humans; Indoles; Lung Neoplasms; Male; Maxillary Sinus Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pelvic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Radiography; Rare Diseases; Sunitinib | 2008 |
Severe epistaxis with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Epistaxis; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2008 |
[Consensus on the medical treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.
Topics: Angiogenesis Inhibitors; Animals; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Endothelial Growth Factors; Enzyme Inhibitors; Indoles; Lymphokines; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neovascularization, Pathologic; Neurofibromatosis 1; Neurons; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Time Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1999 |